| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Gyre Therapeutics, Inc. (GYRE) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 19 sells. GYRE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Pres | 2.81M | $19.84M | - | |
| CEO | 2.57M | $18.14M | -10,315 | |
| 10% | 2.14M | $15.16M | - | |
| Dir | 100.0K | $707.0K | - | |
| CFO | 95.1K | $672.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | Luo Ying | Chief Executive Officer | Sell | 10,315 | $8.04 | $82,927.23 | -0.2% | - | - | |
| May 28, 2025 | Ma Songjiang84 | President | Sell | 2,558 | $10.23 | $26,179.06 | - | -17.8% | - | |
| May 23, 2025 | Ma Songjiang84 | President | Sell | 2,182 | $10.91 | $23,803.68 | - | -13.0% | - | |
| May 21, 2025 | Ma Songjiang84 | President | Sell | 4,000 | $11.04 | $44,160.00 | - | -27.4% | - | |
| May 19, 2025 | Ma Songjiang84 | President | Sell | 4,000 | $11.21 | $44,840.00 | - | -29.3% | - | |
| May 15, 2025 | Ma Songjiang84 | President | Sell | 2,020 | $10.69 | $21,586.00 | - | -25.0% | - | |
| May 13, 2025 | Ma Songjiang84 | President | Sell | 4,000 | $10.97 | $43,860.00 | - | -38.5% | - | |
| Mar 21, 2025 | Ma Songjiang84 | President | Sell | 174 | $10.00 | $1,740.00 | - | -16.9% | -30.8% | |
| Mar 20, 2025 | Ma Songjiang84 | President | Sell | 4,000 | $10.11 | $40,440.00 | - | -18.5% | -34.2% | |
| Mar 18, 2025 | Ma Songjiang84 | President | Sell | 2,242 | $11.89 | $26,658.08 | - | -6.3% | -18.2% |